Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Abstract: A container for unit dose liquid detergent products, said container comprising a lid and a base, wherein at least 50% of the lid and/or base comprise a biodegradable material, wherein said base and top are co-operable so as to form a closed container and which is openable to access the contents by pulling them apart, said lid and base comprising a barrier coating and optional adhesive for adhering the barrier coating to the lid and base, said container comprising a plurality of unit dosed detergent products and wherein said barrier coating and optional adhesive comprises from 0.1 to 5% wt. of the container in the absence of the unit dose detergent products.

Abstract: A package comprising at least one layer of biodegradable material and containing a plurality of unit dose products, at least one unit dose product comprising a detergent composition within a sealed compartment formed by a water soluble film, said film being printed on an inner surface, facing the detergent composition.

Abstract: A package comprising at least one layer of biodegradable material and containing a plurality of unit dose products, at least one unit dose product comprising a detergent composition comprising sequestrant within a sealed compartment formed by a water soluble film, said package comprising a child-resistant closure mechanism.

Abstract: A container for unit dose liquid detergent pouches, said container comprising a lid and a base, wherein said base and top are co-operable so as to form a closed container and which is openable to access the contents by pulling them apart, said lid comprising paper with a weight average cellulose fibre length of from 1 to 5 mm, said container comprising a plurality of unit dosed detergent products and wherein said base comprises paper with a weight average cellulose fibre length of at least 2 mm.

Abstract: A package comprising at least one layer of biodegradable material and containing a plurality of unit dose products, at least one unit dose product comprising a detergent composition comprising hydrogenated castor oil within a sealed compartment formed by a water soluble film.

Abstract: A packaged laundry product comprising packaging and perfume particles contained in said packaging; wherein the packaging comprises a cylindrical receptacle formed from a material comprising cellulosic fibres, wherein the receptacle comprises a mechanism for impeding a child's access to the container; and wherein the perfume particles comprise carrier material and perfume components.

Abstract: A package comprising at least one layer of biodegradable material and containing a plurality of unit dose products, at least one unit dose product comprising a detergent composition comprising hydrogenated castor oil within a sealed compartment formed by a water soluble film.

Abstract: A kit for colouring hair comprising: i) a first container containing a composition comprising an oxidative dye; and ii) a second container containing a composition comprising a per-oxygen generating material, in which the second container comprises sides of height X mm, a first end closed by a bottom of external diameter Y mm and a second end opposite the first, having a opening of internal diameter Z mm in which the ratio of X to Y is less than 1:1 and the internal diameter Z mm differs by 15% or less from the external diameter Y mm and in which the internal diameter Z mm is from 60 to 80 mm.

Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R6, R7, L, X and Y are as defined in the specification; together with processes and intermediates for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.

Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R6, R7, L, X and Y are as defined in the specification; together with processes and intermediates for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.

Abstract: A method and apparatus for automatically reconfiguring a print driver for an image production device is disclosed. The method may include receiving a request to print a print job from a user, wherein the print job includes one or more print job parameters, determining if the one or more print job parameters violate one or more print policies, wherein if it is determined that the one or more print job parameters violate one or more print policies, notifying the user that the one or more print policies have been violated, prompting the user to select to have the print driver reconfigured to adhere to the one or more print policies that were violated, determining if the user selected to reconfigure the print driver, wherein if it is determined that the user selected to reconfigure the print driver, reconfiguring the print driver to adhere to the one or more print policies that were violated, and sending a signal to print the requested print job.

Abstract: An antipsychotic and GlyT1 inhibitor combination is disclosed. The antipsychotic and GlyT1 inhibitor combination may be employed in the prevention and treatment of symptoms of schizophrenia. Pharmaceutical compositions and treatments comprising an antipsychotic and a GlyT1 inhibitor for treating symptoms of schizophrenia are thus also disclosed.

Abstract: Methods and system of providing benefit plan administration. A method of providing benefit plan administration to a first sponsor having at least one participant enrolled in a benefit plan can include electronically receiving benefit plan information from the first sponsor, electronically providing benefit plan information to the first sponsor, and electronically providing benefit plan information to the at least one participant.

Abstract: A method for the preparation of carbonyl difluoride which comprises contacting carbonyl chloride fluoride with an active carbon catalyst.